Landos Biopharma, Inc. Common Stock
LABP
LABP was delisted on the 23rd of May, 2024.
8 hedge funds and large institutions have $6.27M invested in Landos Biopharma, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 12 closing their positions.
35% more capital invested
Capital invested by funds: $4.63M → $6.27M (+$1.64M)
60% less funds holding
Funds holding: 20 → 8 (-12)
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$44K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$27.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$25.7K |
| 4 |
Renaissance Technologies
New York
|
-$24K |
| 5 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$21.9K |
LABP Hedge Fund Activity: Q2 2023 in Review
8 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Landos Biopharma, Inc. Common Stock (LABP) for Q2 2023, worth a combined $6.27M — up 35% from $4.63M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of LABP and 0 opened new positions — a net loss of 12 holders — while 6 trimmed existing stakes and 1 added.
The largest buyer was Royal Bank of Canada, adding an estimated $1.9K. The largest seller was Macquarie Group, exiting entirely with an estimated $44K sold.
- 8 institutional investors held Landos Biopharma, Inc. Common Stock (LABP) as of Q2 2023, down from 20 in Q1 2023.
- Funds reported $6.27M of Landos Biopharma, Inc. Common Stock stock for Q2 2023, up 35% quarter-over-quarter.
- 0 funds opened new Landos Biopharma, Inc. Common Stock positions in Q2 2023 and 12 closed out, a net change of -12 holders.
- The largest Landos Biopharma, Inc. Common Stock buyer in Q2 2023 was Royal Bank of Canada, an estimated $1.9K added.
- The largest Landos Biopharma, Inc. Common Stock seller in Q2 2023 was Macquarie Group, an estimated $44K sold.
Based on aggregated 13F filings for Q2 2023.